Showing 4971-4980 of 8126 results for "".
- Skin of Color Seminar Series to Provide Latest Research and Practical Pearls for Dermatologic Treatment of Skin of Colorhttps://practicaldermatology.com/news/skin-of-color-seminar-series-to-provide-latest-evidence-based-research-and-practical-pearls-for-dermatologic-treatment-of-skin-of-color/2457859/Now in its tenth year, the Skin of Color Seminar Series (SOCSS) will be the largest medical education event of 2018 dedicated to providing dermatologists with evidence-based research and practical pearls in treating skin of color, including patients with multiracial backgrounds. SOCSS, which will
- BrandMD Launches New Tinted, Physical Sunscreenhttps://practicaldermatology.com/news/brandmd-launches-new-tinted-physical-sunscreen/2457863/BrandMD introduced their newest sunscreen, HA Physical Tint SPF 44. HA Physical Tint SPF 44 is a water-resistant, mineral-based formulation to provide well-rounded coverage against UVA and UVB UV radiation. In addition to its chemical-free active ingredients, the formulation also contains antioxi
- SkinCeuticals US Taps Christina Fair as New GMhttps://practicaldermatology.com/news/skinceuticals-us-taps-christina-fair-as-new-gm/2457861/Christina (Tina) Fair is the new General Manager at SkinCeuticals US. Tina joins the US team from the SkinCeuticals DMI, where she has been the Vice President of Global Marketing since 2015. During her time in the DMI, Tina led the development o
- Galderma Enters into Long-term Research Agreement on AD with Icahn School of Medicine at Mount Sinai and Northwestern University Feinberg School of Medicinehttps://practicaldermatology.com/news/galderma-enters-into-long-term-research-agreement-on-ad-with-icahn-school-of-medicine-at-mount-sinai-and-northwestern-university-feinberg-school-of-me/2457865/Galderma has signed a joint research agreement on Atopic Dermatitis (AD) with two leading academic institutions—Icahn School of Medicine at Mount Sinai in New York City, and Northwestern University Feinberg School of Medicine in Chicago. This seven-year collaborative agreement aims to enhan
- Thermi and Sinclair Terminate Collaboration on Silhouette Instalifthttps://practicaldermatology.com/news/thermi-and-sinclair-terminate-collaboration-on-silhouette-instalift/2457866/Thermi, an Almirall S.A. company, and Sinclair Pharma have mutually agreed to terminate their collaboration for the marketing of Silhouette Instalift. Both companies have been working through a join
- Dermira Presents Positive Data on Treating Pediatric Patients with Axillary Hyperhidrosishttps://practicaldermatology.com/news/dermira-presents-positive-data-on-treating-pediatric-patients-with-axillary-hyperhidrosis/2457873/Dermira, Inc. presented new findings from its glycopyrronium tosylate (formerly DRM04) Phase 3 clinical program showing that when applied topically, the investigational therapy improved disease severity, reduced sweat production and was associated with improved quality of life outcomes for pediat
- Some Parents Just Don't Understand Risks of Indoor Tanninghttps://practicaldermatology.com/news/some-parents-just-dont-understand-risks-of-indoor-tanning/2457878/Dads, parents who had used indoor tanning devices themselves and those who reported that they had never received skin cancer prevention counseling from their child’s doctor are less likely to believe adolescent indoor tanning is harmful, a new survey shows. To investigate parents&rs
- Lilly: New Taltz Data and Pipeline Update to be Presented at AAD Annual Meetinghttps://practicaldermatology.com/news/lilly-new-taltz-data-and-pipeline-update-to-be-presented-at-aad-annual-meeting/2457885/Eli Lilly and Company will present new data for Taltz® (ixekizumab), baricitinib, and mirikizumab at the American Academy of Dermatology (AAD) annual meeting in San Diego. The data include eight abstracts for Tal
- FDA Accepts Ortho Dermatologics' NDA For Jemdel Plaque Psoriasis Treatmenthttps://practicaldermatology.com/news/fda-accepts-ortho-dermatologics-filing-for-jemdel-plaque-psoriasis-treatment/2457889/The FDA has accepted the New Drug Application for Jemdel (halobetasol propionate 0.01%) (IDP-122) lotion from Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. If approved, Jemdel will be the first high-potency topical steroid treatment for plaque psoriasis with dosin
- NanOlogy Enrolls First Patient in Clinical Trial for Cutaneous Metastaseshttps://practicaldermatology.com/news/nanology-enrolls-first-patient-in-clinical-trial-for-cutaneous-metastases/2457887/NanOlogy™, a clinical-stage pharmaceutical development company and affiliate of DFB Pharmaceuticals, has enrolled the first patient in a Phase 1/2 clinical trial of a submicron particle paclitaxel topical anhydrous ointment for the treatment of cutaneous metastases. The open label dose esca